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Abstract
Background: Chronic kidney disease is highly prevalent across the globe with more than 2 million people
worldwide requiring renal replacement therapy. Interdialytic weight gain is the change in body weight between
two sessions of haemodialysis. Higher interdialytic weight gain has been associated with an increase in mortality
and adverse cardiovascular outcomes. It has long been questioned whether using a lower dialysate sodium
concentration during dialysis would reduce the interdialytic weight gain and hence prevent these adverse
outcomes.
Methods: This study was a single blinded cross-over study of patients undergoing twice weekly haemodialysis at
the Aga Khan University Hospital, Nairobi and Parklands Kidney Centre. It was conducted over a twelve-week period
and patients were divided into two groups: dialysate sodium concentration of 137 meq/l and 140 meq/l. These
groups switched over after a six-week period without a washout period. Univariate analysis was conducted using
Fisher’s exact test for categorical data and Mann Whitney test for continuous data.
Results: Forty-one patients were included in the analysis. The mean age was 61.37 years, and 73% were males. The
mean duration for dialysis was 2.53 years. The interdialytic weight gain was not significantly different between the
two groups (2.14 for the 137 meq/l group and 2.35 for the 140 meq/l group, p = 0.970). Mean blood pressures were
as follows: pre-dialysis: DNa 137 meq/l: systolic 152.14 ± 19.99, diastolic 78.99 ± 12.20, DNa 140 meq/l: systolic
156.95 ± 26.45, diastolic 79.75 ± 11.25 (p = 0.379, 0.629 respectively). Post-dialysis: DNa 137 meq/l: systolic 147.29 ±
22.22, diastolic 77.85 ± 12.82 DNa 140 meq/l: systolic 151.48 ± 25.65, diastolic 79.66 ± 15.78 (p = 0.569, 0.621
respectively).
Conclusion: There was no significant difference in the interdialytic weight gain as well as pre dialysis and post
dialysis systolic and diastolic blood pressures between the two groups. Therefore, using a lower dialysate sodium
concentration does not appear useful in altering the interdialytic weight gain or blood pressure although further
studies are warranted with a larger sample size, taking into account residual renal function and longer duration for
impact on blood pressures.
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Background
Chronic kidney disease (CKD) is the presence of kidney
damage or decreased kidney function for three or more
months, irrespective of the cause. Globally CKD has a
prevalence of 13.4%, with 10.6% being in stage 3–5 of the
Kidney Disease Improving Global Outcomes (KDIGO)
classification of CKD between the year 2000 to 2014 [1].
The mortality rate for patients with CKD globally is also
high, particularly for those on renal replacement therapy
[2]. More than 2 million people globally are requiring
renal replacement therapy. However, there is less renal replacement therapy in the developing world due to lack of
access and affordability issue [3]. This has resulted in patients with End Stage Renal Disease (ESRD) having less
than the recommended number of sessions of dialysis.
The current recommendations as per the Kidney Disease
Outcomes Quality Initiative (KDOQI) guidelines for
haemodialysis adequacy are geared towards more frequent
and shorter duration of dialysis [4]. Unfortunately, this is
far from the case in sub-Saharan Africa (SSA). In a study
done at Kenyatta National Hospital in Kenya, 98.15% of
patients underwent haemodialysis less than three times a
week [5]. The health insurance scheme in Kenya (National
Health Insurance Fund - NHIF) covers two sessions of
dialysis per week, and those getting three or more sessions
per week have to cover the cost of dialysis themselves,
which poses a great challenge as far as moving towards reduced morbidity and mortality from ESRD [6].
Usually, the operator of the dialysis machine (nurse)
must set the dialysate concentration for the dialysis session. During the process of dialysis, sodium is lost from
the blood by ultrafiltration into the dialysate fluid. According to Flythe et al., the dialysate sodium concentration therefore has to be lower than the serum sodium so
as to allow diffusion to occur and the serum sodium to
be lowered (dialysate sodium at least 2 meq/l lower than
serum sodium). Using a higher dialysate sodium concentration results in ‘sodium-loading’ and thus activates the
centre of thirst in the hypothalamus which makes the
patient drink more water with subsequent weight gain
and volume expansion. There is also an increase in sympathetic tone and release of vasopressin which may result in increased blood pressure and cardiovascular
sequelae [7]. Moret et al. had a different view on this, focusing on ioninc mass balance, where diffusive ion influx
occurred when the dialysate sodium was approximately
5 meq/l greater than the serum sodium [7].
Interdialytic weight gain is ‘the change in body weight
between two sessions of haemodialysis [8]. With time,
the set dialysate sodium concentration has gradually
evolved from 126.5 meq/l in the 1940s, to around 140
meq/l in the 1990s, but there is no consensus on the optimal dialysate sodium concentration [9]. There has been
conflicting evidence, but many studies suggest that with
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a higher dialysate sodium there is a higher interdialytic
weight gain and higher blood pressures. There has also
been a trend towards increased mortality, heart failure
and major cardiac events (nonfatal myocardial infarction,
nonfatal ischemic stroke, or cardiovascular death) as well
as hospitalisations in patients with a higher interdialytic
weight gain [10, 11].
Therefore, the aim of this study was to determine if dialysate sodium concentration has any bearing on interdialytic weight gain and blood pressure control. Most
studies that have been done are observational with very
few clinical trials. Furthermore, in most centres where
these studies were done, patients were undergoing thrice
weekly dialysis. In our set-up, majority of our patients
undergo twice weekly dialysis, which would predispose
them to a higher interdialytic weight gain due to a longer duration between dialysis sessions.
The primary objective was to determine the association between the dialysate sodium concentration and
interdialytic weight gain in patients undergoing haemodialysis twice weekly. The secondary objective was to determine the relationship between dialysate sodium
concentration and blood pressure in patients undergoing
haemodialysis twice weekly.

Methods
Study setting

The study setting was the Aga Khan University Hospital
dialysis unit and Parklands Kidney Centre. The Aga
Khan University Hospital is a private, not-for-profit
teaching hospital and the dialysis unit at the hospital has
9 dialysis machines, with approximately 18 patients
undergoing dialysis every day. There are approximately
48 patients in total on dialysis at the unit, out of which
30 are on twice-weekly dialysis. Parklands Kidney Centre
is an outpatient dialysis unit that has 19 dialysis machines and approximately 90 patients in total, out of
which approximately 45 are on twice-weekly dialysis.
Study design and subjects

The study was a randomized single blind crossover study
design. Each group was dialysed using a dialysate sodium
of 140 and 137 meq/l at different time periods. The
study was conducted at the Aga Khan University Hospital dialysis unit and Parklands Kidney Centre dialysis
unit in Nairobi, Kenya on patients undergoing twice
weekly dialysis over a period of 12 weeks.
The inclusion criteria was as follows: age greater than
18 years, patients undergoing dialysis twice a week, patients who consented to be a part of the study. The exclusion criteria was as follows: patients with blood
pressures less than 100/60, hospital in-patients. Withdrawal criteria was as follows: patients who develop
intradialytic hypotension (reduction in systolic blood
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pressure of 20 mmHg or a reduction in MAP of 10
mmHg accompanied by symptoms such as muscle
cramps, abdominal discomfort, dizziness, nausea, vomiting, yawning, sighing, restlessness, or anxiety) [12, 13].
Figure 1 shows the study flow. The first group of patients were dialysed using a DNa of 140 meq/l for 6
weeks, followed by 137 meq/l for the remaining 6 weeks.
The second group were dialysed using a DNa of 137
meq/l for 6 weeks, followed by 140 meq/l for the
remaining 6 weeks. A total of 41 patients were included
in the analysis.
Statistical analysis

Categorical data were presented as frequencies and percentages whereas continuous data were presented as
means and standard deviations. Univariate analysis was

Fig. 1 Participant flowchart
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conducted using Fisher’s exact test for categorical data
and Mann Whitney test for continuous data. The comparison between IDWG and mean systolic and diastolic
blood pressure with each sodium group chosen for this
study was conducted using the mean IDWG and mean
systolic/diastolic blood pressure using Mann Whitney test.

Results
Demographic and clinical characteristics

The mean age of participants was 61.39 years (SD =
13.82) with a predominantly male population (73%).
The most common cause of CKD in these patients
was hypertension, followed by diabetes mellitus. Most
patients were oliguric. Fifty-nine percent of patients
had a fistula for dialysis access, whereas the remainder had internal jugular permanent dialysis catheters.
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Table 1 Demographic and clinical characteristics of study
participants
Age (years)

61.39 ± 13.82

Gender
Female

11 (27%)

Male

30 (73%)

Cause of ESRD (n (%))
Diabetes mellitus

24 (59%)

Hypertension

33 (80%)

HIV

3 (7%)

Glomerulonephritis

3 (7%)

Multiple myeloma

1 (2%)

Contrast induced nephropathy

1 (2%)

Obstructive uropathy

1 (2%)

Non-steroidal anti inflammatory drugs

2 (5%)

Urine output
Anuric (< 100 ml/day)

5 (13%)

Non-oliguric (> 400 ml/day)

12 (31%)

Oliguric (100–400 ml/day)

22 (56%)

Dialysis access
Fistula

24 (59%)

Permanent catheter

17 (41%)

Diuretic use
No

21 (55%)

Yes

17 (45%)

No. of years on dialysis

Blood pressure

The mean pre-dialysis systolic blood pressure was152.14
151.54 in the low DNa group and 156.95156.05 in the
high DNa group, while the mean pre-dialysis diastolic
blood pressure was 78.99 in the low DNa group and
79.8580.81 in the high DNa group. The average postdialysis systolic blood pressure was 147.296 in the low
DNa group and 151.48 in the high DNa group, while the
average post-dialysis diastolic blood pressure was 77.85
in the low DNa group and 79.6680 in the high DNa
group. None of these differences were statistically significant between both groups as shown in Table 3.
Patients with hypertension were subanalysed to determine if there was a difference in weight gain in this subgroup and there was no significant difference.
Adverse effects

Of the 41 patients, two patients experienced hypotensive
episodes. The first patient had asymptomatic hypotensive
episodes on their 8th and 12th sessions of dialysis at dialysate sodium concentration of 140 meq/l. The second
patient developed an asymptomatic hypotensive episode
in the 4th session of dialysis at dialysate sodium concentration of 137 meq/l and a hypotensive episode on the 2nd
session of dialysis at dialysate sodium concentration 140
meq/l. The latter required disconnection of the dialysis
machine 30 min prior to completion. None of these episodes required saline infusion.

2.53 ± 1.96

Only 45% of patients were on diuretics. The mean
number of years of the patients on dialysis was 2.53.
Table 1 shows the demographic and clinical
characteristics.

Interdialytic weight gain

The primary outcome was the interdialytic weight gain between the two groups of dialysate sodium. The average
interdialytic weight gain was 2.14 kg in the low dialysate
sodium group (DNa 137 meq) and 2.35 in the high dialysate sodium group (DNa 140 meq), with a p value of 0.970,
as seen in Table 2 and Fig. 2.

Discussion
This study has established that there is no association
between dialysate sodium concentration and interdialytic
weight gain. Furthermore, there was no association between dialysate sodium concentration and blood pressure. This was similar to what was found by Beduschi
et al. when comparing DNas of 135 and 138 meq/l where
there was no significant difference in the interdialytic
weight gain or the blood pressure [11]. This was also the
case in the study by Thein et al. where there was no significant difference in the interdialytic weight gain between dialysate sodiums of 141 and 138 meq/l, however
there was a significant reduction in blood pressure with
the lower dialysate sodium used [13]. As much as there
was no statistical significance in the interdialytic weight
gain and blood pressure between the two groups, there

Table 2 Interdialytic weight gain between DNa 137 meq/l and DNa 140 meq/l
Low DNa (dialysate Na: 137)

High DNa (dialysate Na: 140)

P Value

72.27 ± 16.77

72.24 ± 16.69

0.948

Pre dialysis weight (kg)

75.20 ± 17.23

74.37 ± 17.02

0.856

IDWG (kg)

2.14 ± 1.10

2.35 ± 1.38

0.970

Previous post dialysis weight (kg)
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Fig. 2 Interdialytic weight gain between DNa 137 meq/l and DNa 140 meq/l

could still be clinical significance as both parameters
were lower in the lower dialysate sodium group.
It is important to note that there was no exclusion of
patients with residual renal function in this study, yet residual renal function (defined as urine output of greater
than 200 ml/day) theoretically has a physiologic role in
sodium balance [14]. Ipema et al. established that patients with residual diuresis had significantly lower interdialytic weight gain [15, 16]. However in terms of
outcomes, Hecking et al. noted no difference in mortality in patients with or without residual renal function in
spite of the dialysate sodium concentrations used [10].
In the present study, there was no difference in the outcomes in patients with or without residual renal
function.
It has also been established in some studies such as
that by Titze et al. that large amounts of sodium can be
accumulated without water retention by the sodium ions
binding to extracellular matrix components such as

glycosaminoglycans [17]. In addition, there are other sodium reservoirs in the body such as the bone, skin cartilage and connective tissue and as a result, lowering the
dialysate sodium concentration could have caused loss
of sodium without loss of water and had no impact on
the interdialytic weight gain and blood pressure [11].
There is also theory that every individual has their
own individual osmolar setpoint based on parameters
such as dietary salt intake, urinary sodium excretion, tissue sodium stores as well as physiologic response of the
body to sodium. For this reason, a change in the dialysate sodium concentration may not have that much of an
impact on the interdialytic weight gain and blood pressures unless the sodium level is individualised. This was
shown in a study conducted by Radhakrishnan et al.
where they compared a set dialysate sodium concentration of 140 meq/l to an individualised dialysate sodium
concentration. There was a significantly lower interdialytic weight gain and pre-dialysis systolic blood pressure

Table 3 Baseline blood pressure, pre-dialysis and post-dialysis systolic and diastolic blood pressures between the two groups
Low DNa (dialysate Na: 137)

High DNa (dialysate Na: 140)

P Value

Baseline SBP (mmHg)

156.24 ± 25.18

156.51 ± 23.43

0.957

Baseline DBP (mm/Hg)

78.54 ± 14.65

77.7 ± 12.88

0.940

Pre-dialysis SBP (mmHg)

152.14 ± 19.99

156.95 ± 26.45

0.379

Pre-dialysis DBP (mmHg)

78.99 ± 12.20

79.75 ± 11.25

0.629

Post-dialysis SBP (mmHg)

147.29 ± 22.22

151.48 ± 25.65

0.569

Post-dialysis DBP (mmHg)

77.85 ± 12.82

79.66 ± 15.78

0.621
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in those patients who had an individualised dialysate sodium concentration in comparison to the standard dialysate sodium concentration of 140 meq/l [16].
This study showed no significant difference between
the systolic or diastolic blood pressure in both dialysate
sodium concentration groups. Charra et al. described the
concept of ‘lag time’, whereby it takes several months for
the correction of the extracellular volume overload (in
our case from the high sodium) to manifest as improvement in blood pressure [18]. This study was 12 weeks
long and therefore patients may not have completed this
lag time.
An important finding on the study was the average
interdialytic weight gain regardless of the dialysate sodium concentration used. The mean interdialytic weight
gain was 2.14 kg and 2.35 kg for dialysate sodium 137
meq/l and 140 meq/l respectively. Comparing to other
studies, for instance the PanThames renal audit done by
Davenport et al. undergoing dialysis three times a week
showed an interdialytic weight gain range of 1.7 to 2.75
kg [19]. Therefore, interdialytic weight gain in the this
study is comparable to the interdialytic weight gains in
the audit, despite the fact that our patient population
was on twice weekly as opposed to thrice weekly dialysis.
This is an interesting finding given that there are significant resource constraints in Kenya and therefore patients who are recommended to dialyse thrice weekly are
dialysing twice weekly since the NHIF only covers dialysis twice a week. This raises the question as to whether
twice a week dialysis is sufficient for our population considering the interdialytic weight gain is not drastically
high, and in effect mortality and adverse cardiovascular
outcomes may also not be so high. This also raises the
question as to whether our patient population is adhering to fluid restriction and salt restriction practices more
than patients in other parts of the world or whether diuretics in patients with residual renal function have an
effect on this.
It is recommended that the same study be conducted
using a larger sample size to assess the association between dialysate sodium concentration and interdialytic
weight gain. It would also be beneficial to do a comparison
study of the same outcomes of interdialytic weight gain
and blood pressure control in patients on twice weekly
versus thrice weekly dialysis to ascertain whether the different dialysate sodium concentrations are affected by the
frequency of dialysis. A limitation of the study was that
pre-dialysis sodium concentrations were not obtained and
hence dialysate plasma sodium gradient was not calculated. Also, the study duration was short, and therefore as
far as blood pressure is concerned, it would take time for
the effects of a reduction of dialysate sodium to reduce
the extracellular volume and for this to have any effect on
reduction in blood pressure.

Page 6 of 7

Conclusion
In summary, our study showed there was no difference
in the interdialytic weight gain between the low dialysate
sodium concentrations (DNa 137 meq/l) and high dialysate sodium concentration (DNa 140 meq/l) for patients
undergoing twice-weekly haemodialysis. The interdialytic weight gain in both groups was however, generally
lower compared to other studies despite patients undergoing twice-weekly dialysis (as opposed to thriceweekly). Furthermore, the blood pressures were also not
different in either dialysate sodium group and this was
similar to some studies. However our study did not take
into account residual renal function, dietary fluid and
salt intake. In addition, the duration of the study was too
short to compare blood pressures amongst the two
groups due to the lag time between changes in dialysate
sodium and the correction of the extracellular volume.
There is the possibility of clinical significance, despite no
statistical significance for both interdialytic weight gain
and blood pressures, since both were lower in the low
DNa group compared to the high DNa group.
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